Clinical Trial Update: Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MK-3475 (pembrolizumab) in combination with INCB024360 in various selected cancers; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Endometrial Cancer
• Gastric Cancer
• Head and Neck Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Lymphoma
• Melanoma
• Microsatellite-instability High Colorectal Cancer
• Ovarian Cancer
• Renal Cell Carcinoma
• Solid Tumors
• Triple-negative Breast Cancer
• Urothelial Cancer

Drugs mentioned

• INCB024360 (epacadostat)
• MK-3475 (pembrolizumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-19